Why Some Types of Cancer are Harder to Treat Than Others: New Frontiers in Oncology

Over the past thirty years, groundbreaking innovations have saved and transformed thousands of lives of Canadians with cancer. Immunotherapies and precision medicines in particular have made huge strides for many cancer types, including lung, prostate and melanoma, sometimes turning a diagnosis people dread into something that requires less invasive treatments. However, some cancer types are far more difficult to treat: they are particularly aggressive and very hard to eradicate, including rare lung tumours, glioblastoma, as well as pancreatic, liver and gynecological cancers. Other countries have dedicated research programs for hard-to-treat cancers, while the world’s top medical centres are developing new diagnostics and medicines, often using tried-and-true therapeutics combined with new treatments. What can Canadian researchers, clinicians, cancer agencies and patient leaders do differently to shift the survival curves and help cancer patients live longer and with a better quality of life?    Featuring: Robert Bick, Co-Lead, Health Policy Consultant, CanCertainty Anita Angelini, Vice Chair, Brain Cancer Canada Dr. Rodney Ouellette, Sr. Researcher, Founder, Atlantic Cancer Research Institute Dr. Barbara-Ann Millar, Radiation Oncologist, Princess Margaret Cancer Centre Moderator: Fred Horne, Policy Consultant Brain Cancer Canada and Novocure are pleased to participate in this Longwoods Leadership Discussion